Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00435578 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
A Phase 2 study, sponsored by Threshold Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00435578 is a Phase 2 study that was terminated before completion, run by Threshold Pharmaceuticals. The registered enrollment target is 50 participants.
The verdict
NCT00435578, a Phase 2 study, was terminated before completion, sponsored by Threshold Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The primary objectives of this study are: 1. To evaluate the efficacy of glufosfamide in subjects with extensive recurrent sensitive small cell lung cancer (SCLC) as measured by objective response rate 2. To evaluate the safety of glufosfamide in subjects with extensive recurrent sensitive SCLC The secondary objectives are: 1. To evaluate the efficacy of glufosfamide in subjects with extensive recurrent sensitive SCLC as measured by duration of response, progression-free survival and overall survival 2. To evaluate the pharmacokinetics of glufosfamide and isophosphoramide mustard (IPM) The exploratory objectives of this trial are: 1. To evaluate the effect of glufosfamide on lung cancer symptoms 2. To evaluate the role of tumor cell glucose transporter expression on the efficacy of glufosfamide
Interventions
- DRUG Glufosfamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-02 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00435578
The ClinicalTrials.gov registry entry for NCT00435578 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Threshold Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glufosfamide is the first listed.
NCT00435578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00435578 about?
NCT00435578 is a clinical study titled "Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma". The primary objectives of this study are: 1. To evaluate the efficacy of glufosfamide in subjects with extensive recurrent sensitive small cell lung cancer (SCLC) as measured by objective response rate 2. To evaluate the safety of glufosfamide in subjects with extensive recurrent sensitive SCLC Th...
What is the current status of trial NCT00435578?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2007-02. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00435578?
The interventions under investigation include: Glufosfamide (DRUG).
Who is sponsoring clinical trial NCT00435578?
This trial is sponsored by Threshold Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.